Aneta Schuenemeyer
San Antonio, TXNPI 1790774198
Payments from drug & device makers
Across 796 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Lundbeck LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $7K from 30 others
What the payments were for
- Food & beverage$14,315100%
- Education$530%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRINTELLIX$113
- SPRAVATO$101
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 16 | $168,665 |
| RexultiBrexpiprazole | 52 | $84,983 |
| TrintellixVortioxetine Hydrobromide | 87 | $59,198 |
| CaplytaLumateperone Tosylate | 22 | $35,811 |
| Invega SustennaPaliperidone Palmitate | 12 | $27,978 |
| Lisdexamfetamine Dimesylate | 86 | $20,557 |
| AuvelityDextromethorphan Hbr/Bupropion | 21 | $19,418 |
| Loreev XrLorazepam | 27 | $11,648 |
| Lurasidone Hcl | 90 | $9,446 |
| Asenapine Maleate | 35 | $8,273 |
| BelsomraSuvorexant | 17 | $7,954 |
| Ambien CrZolpidem Tartrate | 11 | $7,218 |
| FetzimaLevomilnacipran Hcl | 14 | $6,832 |
| DayvigoLemborexant | 21 | $6,802 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $6,358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $980 | $168,66516 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,241 | $84,98352 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,164 | $59,19887 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,136 | $35,81122 claims |
| Johnson & JohnsonInvega Sustenna, Invega | $1,038 | $33,95424 claims |
| Axsome Therapeutics, Inc.Auvelity | $760 | $19,41821 claims |
| Almatica Pharma LLCLoreev Xr | $774 | $11,64827 claims |
| MerckBelsomra | $63 | $7,95417 claims |
| AbbVieFetzima | $1,130 | $6,83214 claims |
| Eisai Inc.Dayvigo | $135 | $6,80221 claims |
| Indivior Inc.Suboxone | $30 | $6,35812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Texason file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.